Market Overview

UPDATE: Morgan Stanley Initiates AbbVie at Equal-Weight; Heavy Reliance on Humira

Share:
Related ABBV
AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer
Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting
Gilead's Stock Price, Harvoni Pricing, And The Threat Of Merck- A Physician's Perspective (Seeking Alpha)

Morgan Stanley initiated coverage on AbbVie (NYSE: ABBV) with an Equal-weight rating and a $36 price target.

Morgan Stanley noted, "AbbVie (ABBV) biopharma separated from Abbott. We are EW given heavy reliance on Humira and 6% EV/EBITDA premium to global median, offset by attractive yield. Our $36 PT is based on 4.5% yield (assuming div is boosted 2.5% in Dec '13 to $1.64). … AbbVie generates the majority of its $18B in annual revenues from biologicals, including $9B from Humira, a self-injectable drug for arthritis and other autoimmune disorders. It has a highly experienced mgmt team with a strong track record. We project FCF of $5B+ to support $2.5B+ div and external deals to boost pipeline."

AbbVie closed at $35.12 on Wednesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Jul 2015Deutsche BankMaintainsBuy
Jul 2015SunTrust Robinson HumphreyInitiates Coverage onBuy
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ABBV)

Get Benzinga's Newsletters